Are the "other outstanding items" you mention a reference to this last sentence in the recent ann?
"Mesoblast intends to file the resubmission during the next quarter, seeking to address all remaining product characterization issues."
If so I believe "characterization" is a reference to the assay matrix queries from FDA.
The question is why not be specific instead of calling it "clinical data" earlier in the ann given efficacy wasn't an issue, if indeed as I believe they mean assayed samples when they referenced "clinical data".
Cheers.
- Forums
- ASX - By Stock
- MSB
- 2024 Here we go again.
2024 Here we go again., page-397
-
- There are more pages in this discussion • 212 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.07 |
Change
-0.025(2.29%) |
Mkt cap ! $1.216B |
Open | High | Low | Value | Volume |
$1.10 | $1.10 | $1.06 | $4.942M | 4.613M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 70659 | $1.07 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.07 | 43531 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 70659 | 1.065 |
10 | 321922 | 1.060 |
10 | 163165 | 1.055 |
18 | 145872 | 1.050 |
5 | 82472 | 1.045 |
Price($) | Vol. | No. |
---|---|---|
1.070 | 43531 | 2 |
1.075 | 45000 | 1 |
1.080 | 12400 | 2 |
1.085 | 37622 | 4 |
1.090 | 28097 | 2 |
Last trade - 16.10pm 20/06/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Chairman
Nick Poll
Executive Chairman
Previous Video
Next Video
SPONSORED BY The Market Online